Recent advances in nanozyme–CRISPR/Cas biosensors
Chemical Communications · 2025
DOI: 10.1039/d5cc05585g ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Chemical Communications, 2025. Verfasst von Limei Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Precision Medicine Translational Research Center (PMTRC), West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China. baihao@wchscu.edu.…. Hauptthemen laut MEDLINE: Biosensing Techniques, CRISPR-Cas Systems, Nanostructures. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 146 Literaturangaben. Gefördert von: Fundamental Research Funds for the Central Universities, National Natural Science Foundation of China.
Abstract (Originalsprache)
Nanozyme enhanced CRISPR/Cas couples the high catalytic efficiency of nanozymes with the sequence-specific recognition of CRISPR/Cas, delivering a versatile biosensing platform for point-of-care diagnostics and bioanalysis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Precision Medicine Translational Research Center (PMTRC), West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China. baihao@wchscu.edu.cn.
- Institute of Fundamental and Frontier Sciences, University of Electronic Science and Technology of China, Chengdu 610054, Sichuan, China.
Förderung
- Fundamental Research Funds for the Central Universities
- National Natural Science Foundation of China
Zitieren
APA
Zhang, L., He, X., Hu, J., Bai, H., Yao, Y., & Hu, W. W. (2025). Recent advances in nanozyme–CRISPR/Cas biosensors. Chemical Communications. https://doi.org/10.1039/d5cc05585g
Vancouver
Zhang L, He X, Hu J, Bai H, Yao Y, Hu WW. Recent advances in nanozyme–CRISPR/Cas biosensors. Chemical Communications. 2025. doi:10.1039/d5cc05585g
BibTeX
@article{Zhang2025,
author = {Zhang, Limei and He, Xun and Hu, Jie and Bai, Hao and Yao, Yongchao and Hu, Wenchuang Walter},
title = {Recent advances in nanozyme–CRISPR/Cas biosensors},
journal = {Chemical Communications},
year = {2025},
doi = {10.1039/d5cc05585g}
}
EUVIMED